Core Insights - Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [3] - The company will present at two upcoming investor conferences, highlighting its commitment to engaging with investors [1][2] Company Overview - Candel Therapeutics specializes in off-the-shelf multimodal biological immunotherapies that aim to elicit individualized, systemic anti-tumor immune responses [3] - The company has two clinical stage platforms: one based on genetically modified adenovirus and the other on herpes simplex virus (HSV) gene constructs [3] - The lead product candidate from the adenovirus platform, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma, as well as a pivotal phase 3 trial in localized prostate cancer [3] - The lead product candidate from the HSV platform, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma [3] - Candel's enLIGHTEN™ Discovery Platform utilizes human biology and advanced analytics to develop new viral immunotherapies for solid tumors [3]

Core Viewpoint - Candel Therapeutics, Inc. announced that an abstract for an oral presentation regarding its phase 3 clinical trial of CAN-2409 in localized prostate cancer has been accepted for the 2025 ASCO Annual Meeting, highlighting the company's focus on developing immunotherapies for cancer treatment [1]. Group 1: Clinical Trial and Presentation Details - The oral presentation will feature data from the phase 3 clinical trial of CAN-2409, targeting patients with intermediate-to-high risk localized prostate cancer [1]. - The session is scheduled for June 3, 2025, at the ASCO Annual Meeting in Chicago, IL, with Dr. Theodore DeWeese as the presenter [8]. Group 2: Product Information - CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV-tk gene to tumors, inducing a systemic immune response against cancer cells [5]. - The therapy has shown promising results in previous trials, including a significant improvement in disease-free survival when combined with standard radiation therapy in localized prostate cancer [6]. Group 3: Clinical Development and Regulatory Designations - Candel's clinical development program for CAN-2409 includes positive phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, as well as a successful phase 3 trial in localized prostate cancer [6][9]. - The FDA has granted Fast Track Designation for CAN-2409 for multiple cancer types, including localized prostate cancer and PDAC, indicating its potential therapeutic significance [9].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN- 2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radioth ...

Core Insights - Candel Therapeutics Inc has presented promising clinical data from a Phase 2a study of its immunotherapy candidate CAN-2409 for advanced non-small cell lung cancer, particularly in patients who have exhausted standard treatment options [1][2] - The study indicates that CAN-2409 may double the expected median overall survival for patients who have failed multiple lines of chemotherapy and immune checkpoint inhibitors [2][6] Patient Population - The study enrolled patients with advanced non-small cell lung cancer, primarily those with stage four metastatic disease and poor prognostic indicators, including low PD-L1 expression and a history of smoking [1][4][5] - 90% of participants had stage four metastatic disease and had previously failed all available treatments, indicating a very poor prognosis [4][5] Clinical Outcomes - The results showed that 37% of patients were still alive two years after treatment with CAN-2409, which is significantly longer than expected for this patient population [3][6] - Some patients have survived beyond three or four years, which is notable given their progressive metastatic lung cancer [3] Treatment Comparison - The standard of care for this patient population is docetaxel chemotherapy, which has a median overall survival of no more than 10.8 months [5] - CAN-2409 has shown potential to extend overall survival significantly beyond this benchmark, providing hope for patients with limited options [6][9] Future Steps - The company plans to conduct a larger, registration-enabling clinical trial to further validate these findings, aligning with key academic experts and the FDA [6][7] - The timeline for this next phase has not yet been announced, but the company is actively engaging with experts to expedite the process [7] Broader Implications - The application of CAN-2409 may extend beyond lung cancer, with indications of similar efficacy in pancreatic cancer, another challenging disease [8] - The treatment is generally well tolerated, with mild flu-like symptoms lasting less than 24 hours, and requires only two administrations to educate the patient's immune system to control the tumor [9]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Candel Therapeutics announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer (NSCLC) who inadequately responded to immune checkpoint inhibitor (ICI) treatment, showing a median overall survival (mOS) of 24.5 months in evaluable patients [1][5] - The study demonstrated a significant survival benefit compared to standard treatments, with 37% of patients with progressive disease alive two years after CAN-2409 administration [1][5] - The treatment showed improved mOS in non-squamous NSCLC patients, with a mOS of 25.4 months observed in this subgroup [2][5] Clinical Trial Results - The final analysis included 46 evaluable patients, with a median follow-up time of 32.4 months, revealing a long tail of survival [1][4] - Patients with progressive disease at baseline had a mOS of 21.5 months, significantly exceeding the 9.8-11.8 months reported for standard docetaxel chemotherapy [5][8] - A systemic immune response was observed in approximately two-thirds of patients, indicating an abscopal effect [5][8] Safety and Tolerability - CAN-2409 maintained a favorable safety and tolerability profile throughout the extended follow-up period, with no new safety signals identified [5][8] - Dropout rates during the trial were comparable to other clinical trials in similar populations, indicating the treatment's feasibility [4][6] Future Development - Based on positive findings, Candel plans to advance the development program for CAN-2409, including preparations for a potentially registrational clinical trial in NSCLC patients with non-squamous histology [7][10] - The FDA has granted Fast Track Designation for CAN-2409 in combination with ICI treatment for stage III/IV NSCLC patients resistant to first-line therapy [7][10] About CAN-2409 - CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus designed to induce a systemic immune response against tumors [8][9] - The treatment has shown encouraging activity in various solid tumors and has been well tolerated in over 1,000 patients [9][11]

Core Viewpoint - Candel Therapeutics, Inc. (CADL) has experienced a 21% decline in stock price over the past four weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be exhausting [2][4]. - This pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, reflecting buying interest [3][4]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [4]. Fundamental Analysis - Recent upward revisions in earnings estimates for CADL serve as a bullish indicator, correlating strongly with near-term stock price movements [6]. - The consensus EPS estimate for the current year has increased by 3.5% over the last 30 days, indicating analysts' optimism about the company's earnings potential [7]. - CADL holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Candel Therapeutics has entered a strategic commercial partnership with IDEA Pharma to enhance the development and commercialization of its lead asset, CAN-2409, which is focused on cancer treatment [1][3][4] Group 1: Partnership Details - The partnership will provide Candel with strategic commercial input from IDEA throughout the development and commercialization process for CAN-2409 [1][3] - IDEA Pharma will assist in guiding Candel's commercial strategy and support its projects related to CAN-2409, leveraging their expertise in oncology commercialization [3][4] - This collaboration is expected to last through 2026, coinciding with Candel's preparation for a Biologics License Application (BLA) submission for CAN-2409 [4] Group 2: Clinical Data and Product Information - CAN-2409 has shown promising results in a phase 3 clinical trial for localized prostate cancer, demonstrating a 30% reduction in disease recurrence and an 80.4% pathological complete response rate compared to 63.6% in the placebo group [2][9] - The product is an investigational, off-the-shelf, replication-defective adenovirus designed to induce an immune response against tumors by delivering the HSV-tk gene [7][8] - Candel is also evaluating CAN-2409 in non-small cell lung cancer (NSCLC) and has reported significant survival benefits in other cancer types, including pancreatic ductal adenocarcinoma (PDAC) [9][10] Group 3: Company Background - Candel Therapeutics is focused on developing multimodal biological immunotherapies to elicit systemic anti-tumor immune responses [10] - The company has established two clinical-stage platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 being the lead candidate from the adenovirus platform [10] - Candel's other candidate, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma, showing promising results in terms of overall survival [10]